Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Circulation

Retrieve available abstracts of 30 articles:
HTML format

Single Articles

    April 2024
  1. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
    HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
    Circulation. 2024;149:1183-1201.
    PubMed     Abstract available

    February 2024
  2. STONE NJ, Blum C
    If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
    Circulation. 2024;149:427-429.

    January 2024
  3. SANTOS RD, Cuchel M
    LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Circulation. 2024;149:363-366.

    November 2023
  4. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
    BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
    Circulation. 2023;148:1764-1777.
    PubMed     Abstract available

  5. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    PubMed     Abstract available

    October 2023
  6. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    PubMed     Abstract available

  7. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    PubMed     Abstract available

    September 2023
  8. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.

  9. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.

  10. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.

    July 2023
  11. LAGU T, Schroth SL, Haywood C, Heinemann A, et al
    Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review.
    Circulation. 2023;148:268-277.
    PubMed     Abstract available

  12. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    PubMed     Abstract available

    May 2023
  13. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.

    April 2023
  14. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    PubMed     Abstract available

    October 2022
  15. SHOTWELL MK, Vorla M, Kalra DK
    Very High Cholesterol Mimicking Homozygous Familial Hypercholesterolemia.
    Circulation. 2022;146:1182-1188.

    August 2022
  16. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    PubMed     Abstract available

    May 2022
  17. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    PubMed     Abstract available

    February 2022
  18. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    PubMed     Abstract available

    June 2021
  19. KUEHN BM
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.

  20. ROHATGI A, Westerterp M, von Eckardstein A, Remaley A, et al
    HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.
    Circulation. 2021;143:2293-2309.
    PubMed     Abstract available

    April 2021
  21. POWELL-WILEY TM, Poirier P, Burke LE, Despres JP, et al
    Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2021 Apr 22:CIR0000000000000973. doi: 10.1161/CIR.0000000000000973.
    PubMed     Abstract available

    November 2020
  22. KULLO IJ
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.

    October 2020
  23. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.

    June 2020
  24. KHERA AV, Hegele RA
    What Is Familial Hypercholesterolemia, and Why Does It Matter?
    Circulation. 2020;141:1760-1763.

  25. HOVINGH GK, Lepor NE, Kallend D, Stoekenbroek RM, et al
    Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Circulation. 2020;141:1829-1831.

    May 2020
  26. HU P, Dharmayat KI, Stevens CAT, Sharabiani MTA, et al
    Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Circulation. 2020 May 29. doi: 10.1161/CIRCULATIONAHA.119.044795.

  27. LOUPY A, Coutance G, Bonnet G, Van Keer J, et al
    Identification and characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population Based Study.
    Circulation. 2020 May 4. doi: 10.1161/CIRCULATIONAHA.119.044924.
    PubMed     Abstract available

    April 2020
  28. STONE NJ, Blumenthal RS, Lloyd-Jones D, Grundy SM, et al
    Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1117-1120.

  29. VIRANI SS, Smith SC Jr, Stone NJ, Grundy SM, et al
    Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1121-1123.

    November 2019
  30. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.